Factors Influencing Cardiovascular Prognosis
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Cardiovascular Mortality. Basic parameters: from 50 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Factors Influencing Cardiovascular Prognosis in Hypertensive Patients (Pythia Study)
Overview
The purpose of this study is to identify risks for cardiovascular events in a follow up period of 10 years.
Detailed description
Inclusion criteria
* Age \> 50 years volunteers (2 towns of 15000 residents one in the north and one in the south of Greece) * End points * 5-10 years cardiovascular morbidity and mortality
Measurements at baseline
* Anthropometrics
* Age (M\>55 years; W\>65 years) * Weight-height- BMI * Abdominal obesity (Waist circumference\>102 cm(M), \>88cm (W) Family history * Family history of premature CV disease (M at age\<55 years; W at age\<65 years)
History
* Smoking * Diabetes Mellitus, * Established Heart disease: myocardial infarction; angina; coronary revascularization; heart failure * Established renal disease \[diabetic nephropathy; renal impairment (serum creatinine M\>133, W\>124 mmol/l); proteinuria (\> 300 mg/24 h)\] * Cerebrovascular disease: ischaemic stroke; cerebral haemorrhage; transient ischaemic attack * Peripheral artery disease * Advanced retinopathy: haemorrhages or exudates, papilloedema * Treatment
Measurements
* Measurements Blood pressure
* Clinic BP * 24h ABPM * Home BP
Heart
* Electrocardiographic LVH * Echocardiographic LVH
Vessels
* Carotid wall thickening or plaque * Carotid-femoral pulse wave velocity * Ankle/brachial BP index
Lipids or other risk factors
* Total cholesterol, Tg, HDL, LDL * Plasma creatinine, estimated glomerular filtration rate * Fasting plasma glucose or postload plasma glucose * Microalbuminuria and albumin-creatinine ratio * Glucose tolerance test
* Follow up each 3 year with all the above measurements
Primary outcome measures
- Cardiovascular mortality [Time frame: 10 years]
Secondary outcome measures (1)
- Hospitalization for CV events [Time frame: 10 years]
Eligibility criteria
Inclusion criteria
- All age >50 volunteers
Exclusion criteria
- None
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Cohort
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT00973206 · AUTH20090609